The Chemours Company (NYSE:CC) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 30.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 345,916 shares of the specialty chemicals company's stock after selling 150,157 shares during the period. Principal Financial Group Inc. owned 0.23% of Chemours worth $7,029,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of CC. Matrix Trust Co purchased a new position in Chemours in the third quarter worth about $25,000. Blue Trust Inc. grew its stake in Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 731 shares during the last quarter. Truvestments Capital LLC acquired a new position in Chemours during the 3rd quarter valued at about $35,000. Brooklyn Investment Group purchased a new stake in shares of Chemours during the third quarter valued at $37,000. Finally, Signaturefd LLC lifted its stake in Chemours by 163.7% during the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock valued at $40,000 after acquiring an additional 1,216 shares during the period. Institutional investors own 76.26% of the company's stock.

Chemours Price Performance

CC stock traded up $0.08 during midday trading on Wednesday, hitting $16.90. 1,259,741 shares of the stock were exchanged, compared to its average volume of 1,592,516. The stock's 50-day moving average price is $19.38 and its 200-day moving average price is $20.17. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of 33.80 and a beta of 1.80. The Chemours Company has a fifty-two week low of $15.10 and a fifty-two week high of $32.70. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.08. The business had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business's revenue was up .9% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 earnings per share. Research analysts predict that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.92%. The ex-dividend date was Friday, November 15th. Chemours's dividend payout ratio is presently 200.00%.

Analysts Set New Price Targets

A number of brokerages have weighed in on CC. Morgan Stanley decreased their price objective on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 5th. BMO Capital Markets boosted their price target on shares of Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, October 7th. The Goldman Sachs Group decreased their price target on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating for the company in a research report on Tuesday, September 3rd. Barclays increased their target price on Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $25.00 price objective on shares of Chemours in a report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $24.88.

Insider Activity at Chemours

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares of the company's stock, valued at approximately $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.